C-MET as a new therapeutic target for the development of novel anticancer drugs (original) (raw)

• Benvenuti S, Comoglio PM (2007) The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 213:316–325
  Article PubMed CAS Google Scholar
• Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915–925
  Article PubMed CAS Google Scholar
• Trusolino L, Comoglio PM (2002) Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2:289–300
  Article PubMed CAS Google Scholar
• Peschard P, Fournier TM, Lamorte L et al (2001) Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell 8:995–1004
  Article PubMed CAS Google Scholar
• Abella JV, Peschard P, Naujokas MA et al (2005) Met/hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol Cell Biol 25:9632–9645
  Article PubMed CAS Google Scholar
• Stoker M, Gherardi E, Perryman M, Gray J (1987) Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327:239–242
  Article PubMed CAS Google Scholar
• Gherardi E, Gray J, Stoker M et al (1989) Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement. Proc Natl Acad Sci U S A 86:5844–5848
  Article PubMed CAS Google Scholar
• Nakamura T, Teramoto H, Ichihara A (1986) Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci U S A 83:6489–6493
  Article PubMed CAS Google Scholar
• Naldini L, Weidner KM, Vigna E et al (1991) Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. Embo J 10:2867–2878
  PubMed CAS Google Scholar
• Comoglio PM, Giordano S, Trusolino L (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7:504–516
  Article PubMed CAS Google Scholar
• Stamos J, Lazarus RA, Yao X (2004) Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. Embo J 23: 2325–2335
  Article PubMed CAS Google Scholar
• Zhang YW, Vande Woude GF (2003) HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 88:408–417
  Article PubMed CAS Google Scholar
• Corso S, Comoglio PM, Giordano S (2005) Cancer therapy: can the challenge be MET? Trends Mol Med 11:284–292
  Article PubMed CAS Google Scholar
• Boccaccio C, Comoglio PM (2006) Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6:637–645
  Article PubMed CAS Google Scholar
• Eder JP, Vande Woude GF, Boerner SA, LoRusso PM (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15:2207–2214
  Article PubMed CAS Google Scholar
• Zeng Q, Chen S, You Z et al (2002) Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B. J Biol Chem 277:25203–25208
  Article PubMed CAS Google Scholar
• Tulasne D, Foveau B (2008) The shadow of death on the MET tyrosine kinase receptor. Cell Death Differ 15:427–434
  Article PubMed CAS Google Scholar
• Migliore C, Giordano S (2008) Molecular cancer therapy: can our expectation be MET? Eur J Cancer 44:641–651
  Article PubMed CAS Google Scholar
• Birchmeier C, Gherardi E (1998) Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 8:404–410
  Article PubMed CAS Google Scholar
• Schmidt L, Duh FM, Chen F et al (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68–73
  Article PubMed CAS Google Scholar
• Maina F, Casagranda F, Audero E et al (1996) Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. Cell 87:531–542
  Article PubMed CAS Google Scholar
• Maina F, Pante G, Helmbacher F et al (2001) Coupling Met to specific pathways results in distinct developmental outcomes. Mol Cell 7:1293–1306
  Article PubMed CAS Google Scholar
• Huh CG, Factor VM, Sanchez A (2004) Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A 101:4477–4482
  Article PubMed CAS Google Scholar
• Iyer A, Kmiecik TE, Park M et al (1990) Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene. Cell Growth Differ 1:87–95
  PubMed CAS Google Scholar
• Christensen JG, Burrows J, Salgia R (2005) c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 225:1–26
  Article PubMed CAS Google Scholar
• Zhang YW, Su Y, Volpert OV, Vande Woude GF (2003) Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A 100:12718–12723
  Article PubMed CAS Google Scholar
• Cooper CS, Park M, Blair DG et al (1984) Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311:29–33
  Article PubMed CAS Google Scholar
• Liang TJ, Reid AE, Xavier R (1996) Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. J Clin Invest 97:2872–2877
  Article PubMed CAS Google Scholar
• Soman NR, Correa P, Ruiz BA, Wogan GN (1991) The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc Natl Acad Sci U S A 88:4892–4896
  Article PubMed CAS Google Scholar
• Smolen GA, Sordella R, Muir B et al (2006) Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 103:2316–2321
  Article PubMed CAS Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039–1043
  Article PubMed CAS Google Scholar
• Carracedo A, Egervari K, Salido M et al (2009) FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors. Breast Cancer Res 11:402
  Article PubMed CAS Google Scholar
• Taulli R, Scuoppo C, Bersani F et al (2006) Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 66:4742–4749
  Article PubMed CAS Google Scholar
• Houldsworth J, Cordon-Cardo C, Ladanyi M et al (1990) Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res 50:6417–6422
  PubMed CAS Google Scholar
• Umeki K, Shiota G, Kawasaki H (1999) Clinical significance of c-met oncogene alterations in human colorectal cancer. Oncology 56:314–321
  Article PubMed CAS Google Scholar
• Bean J, Brennan C, Shih JY et al (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104:20932–20937
  Article PubMed Google Scholar
• Tong CY, Hui AB, Yin XL (2004) Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and arraybased comparative genomic hybridization. J Neurosurg 100:187–193
  PubMed CAS Google Scholar
• Beroukhim R, Getz G, Nghiemphu L et al (2007) Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 104:20007–20012
  Article PubMed Google Scholar
• Cappuzzo F, Marchetti A, Skokan M et al (2009) Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 27:1667–1674
  Article PubMed Google Scholar
• Go H, Jeon YK, Park HJ et al (2010) High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol 5(3):305–313
  Article PubMed Google Scholar
• Zeng ZS, Weiser MR, Kuntz E et al (2008) c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett 265:258–269
  Article PubMed CAS Google Scholar
• Park WS, Dong SM, Kim SY et al (1999) Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 59:307–310
  PubMed CAS Google Scholar
• Lee JH, Han SU, Cho H et al (2000) A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19:4947–4953
  Article PubMed CAS Google Scholar
• Seiwert TY, Jagadeeswaran R, Faoro L et al (2009) The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 69:3021–3031
  Article PubMed CAS Google Scholar
• Sattler M, Salgia R (2007) c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep 9:102–108
  Article PubMed CAS Google Scholar
• Ma PC, Kijima T, Maulik G et al (2003) c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63:6272–6281
  PubMed CAS Google Scholar
• Ma PC, Jagadeeswaran R, Jagadeesh S et al (2005) Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65:1479–1488
  Article PubMed CAS Google Scholar
• Jagadeeswaran R, Ma PC, Seiwert TY et al (2006) Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 66:352–361
  Article PubMed CAS Google Scholar
• Puri N, Ahmed S, Janamanchi V et al (2007) c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 13:2246–2253
  Article PubMed CAS Google Scholar
• Puri N, Khramtsov A, Ahmed S et al (2007) A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angio genesis in mouse lung cancer xenografts. Cancer Res 67:3529–3534
  Article PubMed CAS Google Scholar
• Jeffers M, Schmidt L, Nakaigawa N et al (1997) Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A 94:11445–11450
  Article PubMed CAS Google Scholar
• Kong-Beltran M, Seshagiri S, Zha J et al (2006) Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 66:283–289
  Article PubMed CAS Google Scholar
• Graveel C, Su Y, Koeman J et al (2004) Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci U S A 101:17198–17203
  Article PubMed CAS Google Scholar
• Di Renzo MF, Olivero M, Martone T et al (2000) Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19:1547–1555
  Article PubMed CAS Google Scholar
• Aebersold DM, Landt O, Berthou S et al (2003) Prevalence and clinical impact of Met Y1253Dactivating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx. Oncogene 22:8519–8523
  Article PubMed CAS Google Scholar
• Lorenzato A, Olivero M, Patane S et al (2002) Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res 62:7025–7030
  PubMed CAS Google Scholar
• Cañadas I, Arumi M, Lema L et al (2009) MET in small cell lung carcinoma (SCLC): effects of a MET inhibitor in SCLC cell lines and prognostic role of MET status in patients. J Clin Oncol (ASCO Meeting Abstracts) 27:e14617
  Google Scholar
• Danilkovitch-Miagkova A, Zbar B (2002) Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 109:863–867
  PubMed CAS Google Scholar
• Ichimura E, Maeshima A, Nakajima T, Nakamura T (1996) Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 87:1063–1069
  PubMed CAS Google Scholar
• Cipriani NA, Abidoye OO, Vokes E, Salgia R (2009) MET as a target for treatment of chest tumors. Lung Cancer 63:169–179
  Article PubMed Google Scholar
• Garcia S, Dales JP, Charafe-Jauffret E et al (2007) Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol 38:830–841
  Article PubMed CAS Google Scholar
• Olivero M, Rizzo M, Madeddu R et al (1996) Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 74:1862–1868
  PubMed CAS Google Scholar
• Takanami I, Tanana F, Hashizume T et al (1996) Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers. Oncology 53:392–397
  Article PubMed CAS Google Scholar
• Tsao MS, Liu N, Chen JR et al (1998) Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer 20:1–16
  Article PubMed CAS Google Scholar
• Natali PG, Prat M, Nicotra MR et al (1996) Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer 69:212–217
  Article PubMed CAS Google Scholar
• Di Renzo MF, Olivero M, Katsaros D et al (1994) Overexpression of the Met/HGF receptor in ovarian cancer. Int J Cancer 58:658–662
  Article PubMed Google Scholar
• Wong AS, Pelech SL, Woo MM et al (2001) Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis? Oncogene 20:1318–1328
  Article PubMed CAS Google Scholar
• Garcia S, Dales JP, Jacquemier J et al (2007) c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. Br J Cancer 96:329–335
  Article PubMed CAS Google Scholar
• Takeuchi H, Bilchik A, Saha S et al (2003) c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 9:1480–1488
  PubMed CAS Google Scholar
• Sawada K, Radjabi AR, Shinomiya N et al (2007) c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 67:1670–1679
  Article PubMed CAS Google Scholar
• Tolgay Ocal I, Dolled-Filhart M, D’Aquila TG et al (2003) Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 97:1841–1848
  Article PubMed CAS Google Scholar
• Gentile A, Trusolino L, Comoglio PM (2008) The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 27:85–94
  Article PubMed CAS Google Scholar
• Boccaccio C, Gaudino G, Gambarotta G et al (1994) Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF. J Biol Chem 269:12846–12851
  PubMed CAS Google Scholar
• Aguirre Ghiso JA, Alonso DF, Farias EF et al (1999) Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Eur J Biochem 263:295–304
  Article PubMed CAS Google Scholar
• Michieli P, Basilico C, Pennacchietti S et al (1999) Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 18:5221–5231
  Article PubMed CAS Google Scholar
• Koochekpour S, Jeffers M, Rulong S et al (1997) Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 57:5391–5398
  PubMed CAS Google Scholar
• Tuck AB, Park M, Sterns EE et al (1996) Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 148:225–232
  PubMed CAS Google Scholar
• Ferracini R, Olivero M, Di Renzo MF et al (1996) Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene 12:1697–1705
  PubMed CAS Google Scholar
• Ferracini R, Di Renzo MF, Scotlandi K et al (1995) The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 10:739–749
  PubMed CAS Google Scholar
• Rong S, Segal S, Anver M et al (1994) Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci U S A 91:4731–4735
  Article PubMed CAS Google Scholar
• Lokker NA, Mark MR, Luis EA et al (1992) Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. Embo J 11:2503–2510
  PubMed CAS Google Scholar
• Lietha D, Chirgadze DY, Mulloy B et al (2001) Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor. Embo J 20:5543–5555
  Article PubMed CAS Google Scholar
• Matsumoto K, Kataoka H, Date K, Nakamura T (1998) Cooperative interaction between alpha- and beta-chains of hepatocyte growth factor on c-Met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses. J Biol Chem 273:22913–22920
  Article PubMed CAS Google Scholar
• Trusolino L, Pugliese L, Comoglio PM (1998) Interactions between scatter factors and their receptors: hints for therapeutic applications. Faseb J 12:1267–1280
  PubMed CAS Google Scholar
• Chan AM, Rubin JS, Bottaro DP et al (1991) Identification of a competitive HGF antagonist encoded by an alternative transcript. Science 254: 1382–1385
  Article PubMed CAS Google Scholar
• Montesano R, Soriano JV, Malinda KM (1998) Differential effects of hepatocyte growth factor isoforms on epithelial and endothelial tubulogenesis. Cell Growth Differ 9:355–365
  PubMed CAS Google Scholar
• Matsumoto K, Nakamura T (2003) NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 94:321–327
  Article PubMed CAS Google Scholar
• Matsumoto K, Nakamura T (2008) NK4 gene therapy targeting HGF-Met and angiogenesis. Front Biosci 13:1943–1951
  Article PubMed CAS Google Scholar
• Mazzone M, Basilico C, Cavassa S et al (2004) An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest 114:1418–1432
  PubMed CAS Google Scholar
• Michieli P, Mazzone M, Basilico C et al (2004) Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6:61–73
  Article PubMed CAS Google Scholar
• Kong-Beltran M, Stamos J, Wickramasinghe D (2004) The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 6:75–84
  Article PubMed CAS Google Scholar
• Martens T, Schmidt NO, Eckerich C et al (2006) A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 12:6144–6152
  Article PubMed CAS Google Scholar
• Petrelli A, Circosta P, Granziero L et al (2006) Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci U S A 103:5090–5095
  Article PubMed CAS Google Scholar
• Kim KJ, Wang L, Su YC et al (2006) Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 12:1292–1298
  Article PubMed CAS Google Scholar
• Jun HT, Sun J, Rex K (2007) AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 13:6735–6742
  Article PubMed CAS Google Scholar
• Morotti A, Mila S, Accornero P, et al (2002) K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 21:4885–4893
  Article PubMed CAS Google Scholar
• Sattler M, Pride YB, Ma P et al (2003) A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 63:5462–5469
  PubMed CAS Google Scholar
• Christensen JG, Schreck R, Burrows J et al (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63:7345–7355
  PubMed CAS Google Scholar
• Berthou S, Aebersold DM, Schmidt LS et al (2004) The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 23:5387–5393
  Article PubMed CAS Google Scholar
• Zou HY, Li Q, Lee JH et al (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 67:4408–4417
  Article PubMed CAS Google Scholar
• Zhang Y, Guessous F, Kofman A et al (2010) XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs 13:112–121
  PubMed Google Scholar
• Welsh JW, Mahadevan D, Ellsworth R et al (2009) The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol 4:69
  Article PubMed CAS Google Scholar
• Buchanan SG, Hendle J, Lee PS et al (2009) SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther 8:3181–3190
  Article PubMed CAS Google Scholar